Roche rumbles into Europe
After its $16bn transaction in the US market last week, Swiss pharmaceutical Roche is continuing to chip away at the $42bn needed for its Genetech takeover by accessing the euro and sterling markets today. How will the European market compare with the US as the bookrunners market the four year tranche at mid-swaps plus 225bp to 235bp, the seven year at plus 265bp to 275bp, the 12 year at plus 310bp to 320bp and a sterling six year at Gilts plus 270bp? Read EuroWeek on Friday to find out.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts